Screener
Solid Biosciences Inc. SLDB Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | $44,265 | $32,415 | $90,405 | $63,329 |
| General and administrative | 13,119 | 9,278 | 24,287 | 18,416 |
| Total operating expenses | 57,384 | 41,693 | 114,692 | 81,745 |
| Loss from operations | (57,384) | (41,693) | (114,692) | (81,745) |
| Other income, net: | ||||
| Interest income | 3,221 | 2,966 | 5,285 | 5,266 |
| Interest expense | — | (60) | — | (128) |
| Change in fair value of derivative liabilities | (850) | (900) | (2,500) | (2,550) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s operating income?
- Solid Biosciences Inc. (SLDB) reported operating income of -$57.38M in Q2 2026.
- How has Solid Biosciences Inc.'s operating income changed year-over-year?
- Solid Biosciences Inc.'s operating income decreased by 37.6% year-over-year, from -$41.69M to -$57.38M.
- What is the long-term trend for Solid Biosciences Inc.'s operating income?
- Over 4 years (2021 to 2025), Solid Biosciences Inc.'s operating income has grown at a 25.5% compound annual growth rate (CAGR), from -$72.25M to -$179.21M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Solid Biosciences Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude